{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '10.3.1 Temporary Treatment Discontinuation With Investigational Medicinal Product(s)', 'Temporary treatment discontinuation may be considered by the Investigator because of AEs.', 'Reinitiation of treatment with the IMP will be done under close and appropriate clinical and/or', 'laboratory monitoring once the Investigator will have considered according to his/her best medical', 'judgment that the responsibility of the IMP(s) in the occurrence of the concerned event was', 'unlikely and if the selection criteria for the study are still met (refer to Section 7.1 and', 'Section 7.2) AE is sufficiently resolved and unlikely to recur after resuming therapy with IMP.', 'In addition, the following conditions(s) will be cause for temporary treatment discontinuation:', 'Infections or infestations that do not respond to medical treatment', 'Any laboratory abnormality that meets temporary treatment discontinuation criteria as per', 'Appendix K on Guidelines for management of specific laboratory abnormalities', '10.3.2 Permanent Treatment Discontinuation With Investigational Medicinal Product(s)', 'Permanent treatment discontinuation is any treatment discontinuation associated with the', 'definitive decision from the Investigator or the patient not to re-expose the patient to the IMP at', 'any time.', '10.3.3 List of Criteria for Permanent Treatment Discontinuation', 'The patients may withdraw from treatment with the IMP if they decide to do so, at any time and', \"irrespective of the reason, or this may be the Investigator's decision. All efforts should be made to\", 'document the reasons for treatment discontinuation and this should be documented in the CRF or', 'e-CRF.', 'Patients must be withdrawn from the study (ie, from any further investigational product or study', 'procedure) for the following reasons:', 'At their own request or at the request of their legally authorized representative (Legally', 'authorized representative means an individual or judicial or other body authorized under', \"applicable law to consent on behalf of a prospective patient to the patient's participation in\", 'the procedure(s) involved in the research).', \"If, in the Investigator's opinion, continuation in the study would be detrimental to the\", \"patient's well-being\", 'At the specific request of the Sponsor', '-', 'Including some specific circumstances like the Yellow Fever outbreak in Brazil, where', 'patients from affected areas who are not previously vaccinated with yellow-fever', 'vaccine, are to be permanently discontinued from study drug (Section 8.8.1).', 'In the event of a protocol deviation, at the discretion of the Investigator or the Sponsor', 'Any code breaking requested by the Investigator will lead to permanent treatment', 'discontinuation.', 'Pregnancy', 'Property of the Sanofi Group - strictly confidential', 'Page 98', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Anaphylactic reactions or systemic allergic reactions that are related to IMP and require', 'treatment.', 'Diagnosis of a malignancy during study.', 'Any opportunistic infection, such as TB or other infections whose nature or course may', 'suggest an immunocompromised status (See Appendix M).', 'Serum ALT >3 ULN and Total Bilirubin >2 ULN (See Appendix K).', 'Serum ALT >5 ULN if baseline ALT <2 ULN or ALT >8 ULN if baseline ALT >2 ULN', '(Appendix K).', 'Any abnormal laboratory value or ECG parameter will be immediately rechecked for', 'confirmation before making a decision of permanent discontinuation of the IMP for the concerned', 'patient.', '10.3.4 Handling of Patients After Permanent Treatment Discontinuation', 'Patients will be followed-up according to the study procedures as specified in this protocol up to', 'the scheduled date of study completion, or up to recovery or stabilization of any AE to be', 'followed-up as specified in this protocol, whichever comes last. Study Investigators should', 'continue background therapy after treatment discontinuation, as guided by their medical', 'judgment.', 'For patients in Brazil, see Appendix N.', 'Patients who permanently discontinue the study medication will be asked and encouraged to', 'return to the clinic for study visits and participate in assessments according to the visit schedule', 'until the EOS with a 5 day window or up to recovery or stabilization of any AEs. At the time of', 'permanent treatment discontinuation, patients will perform ETD visit with all the assessments', 'defined for the EOT Visit 28. Patients who permanently discontinue early from treatment will not', 'be eligible for the 1-year long-term extension study.', 'For patients who permanently discontinue the study, under exceptional circumstances where there', 'is no possibility for a patient and parent(s)/caregiver(s)/legal guardian(s) to come to the site for', \"the scheduled follow-up visit, a phone contact may be made after Sponsor's approval is given.\", 'During that phone contact, at least information about AEs, concomitant medication and asthma', 'exacerbation events must be collected, and the schedule for these calls should still reflect the visit', 'schedule.', 'Patients who discontinue early from treatment may be asked to return to the clinic to have', 'additional ADA samples collected for analysis based on the overall assessment of antibody titers', 'and clinical presentation at the time of discontinuation.', 'All cases of permanent treatment discontinuation should be entered by the Investigator in the', 'e-CRF when considered as confirmed.', 'Property of the Sanofi Group - strictly confidential', 'Page 99', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}